Dehkordi Korosh Ashrafi, Chaleshtori Morteza Hashemzadeh, Sharifi Mohamadreza, Jalili Ali, Fathi Fardin, Roshani Daem, Nikkhoo Bahram, Hakhamaneshi Mohammad Saeed, Sani Mohammad Reza Mahmoodian, Ganji-Arjenaki Mahboue
Student Research Committee, Kurdistan University of Medical Sciences, Pasdaran Street, Sanandaj, 66177-13446 Iran.
Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Indian J Hematol Blood Transfus. 2017 Sep;33(3):327-332. doi: 10.1007/s12288-016-0694-7. Epub 2016 Jun 17.
MicroRNAs (miRNAs) are small regulatory molecules that negatively regulate gene expression by base-pairing with their target mRNAs. miRNAs have contribute significantly to cancer biology and recent studies have demonstrated the oncogenic or tumor-suppressing role in cancer cells. In many tumors up-regulation miRNAs has been reported especially miR-222 has been shown to be up-regulated in B chronic lymphocytic leukemia (B-CLL). In this study we assessed the effected inhibition of miR-222 in cell viability of B-CLL. We performed inhibition of mir-222 in B-CLL cell line (183-E95) using locked nucleic acid (LNA) antagomir. At different time points after LNA-anti-mir-222 transfection, miR-222 quantitation and cell viability were assessed by qRT-real time polymerase chain reaction and MTT assays. The data were analyzed by independent test and one way ANOVA. Down-regulation of miR-222 in B-CLL cell line (183-E95) with LNA antagomir decreased cell viability in B-CLL. Cell viability gradually decreased over time as the viability of LNA-anti-mir transfected cells was <47 % of untreated cells at 72 h post-transfection. The difference in cell viability between LNA-anti-miR and control groups was statistically significant ( < 0.042). Based on our findings, the inhibition of miR-222 speculate represent a potential novel therapeutic approach for treatment of B-CLL.
微小RNA(miRNA)是一类小的调节分子,通过与靶mRNA碱基配对来负向调节基因表达。miRNA对癌症生物学有重要贡献,最近的研究已证明其在癌细胞中具有致癌或抑癌作用。在许多肿瘤中,已有报道称miRNA上调,尤其是miR-222在B细胞慢性淋巴细胞白血病(B-CLL)中被证明上调。在本研究中,我们评估了抑制miR-222对B-CLL细胞活力的影响。我们使用锁核酸(LNA)反义寡核苷酸在B-CLL细胞系(183-E95)中抑制mir-222。在LNA-抗mir-222转染后的不同时间点,通过qRT-实时聚合酶链反应和MTT试验评估miR-222定量和细胞活力。数据通过独立样本检验和单因素方差分析进行分析。用LNA反义寡核苷酸下调B-CLL细胞系(183-E95)中的miR-222可降低B-CLL细胞的活力。随着时间的推移,细胞活力逐渐下降,因为在转染后72小时,LNA-抗mir转染细胞的活力低于未处理细胞的47%。LNA-抗miR组和对照组之间的细胞活力差异具有统计学意义(P<0.042)。基于我们的研究结果,推测抑制miR-222可能是一种治疗B-CLL的潜在新疗法。